Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics SVP and General Counsel Esther Cho reported an automatic sale of 4,745 shares of common stock. The shares were sold in open-market transactions at a weighted average price of $16.35 per share, with individual trade prices ranging from $16.05 to $16.65.
According to the disclosure, Keros Therapeutics has a “sell-to-cover” policy for tax withholding, and these sales reflect shares sold to satisfy Ms. Cho’s tax obligations upon vesting of restricted stock units. The filing notes the sales were automatic and not at her discretion. After the transactions, she beneficially owned 39,755 shares, including 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Keros Therapeutics, Inc. chief financial officer Keith Regnante reported an automatic open-market sale of common stock tied to tax withholding on vested restricted stock units. He sold 4,739 shares on February 18, 2026 at a weighted average price of $16.35 per share, in multiple trades between $16.05 and $16.65. After these sell-to-cover transactions, he beneficially owns 39,261 shares of Keros Therapeutics common stock directly.
Keros Therapeutics, Inc. announced that President and CEO Jasbir S. Seehra will present at three upcoming healthcare investor conferences. He is scheduled for a corporate presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, all in Eastern time. Webcast links are provided, and replays will be available in the Investors section of Keros’ website for up to 90 days after each event. Keros is a clinical-stage biopharmaceutical company developing protein therapeutics targeting dysfunctional signaling of the TGF-ß family of proteins, with lead candidates rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Keros Therapeutics, Inc. received an updated ownership report from ExodusPoint-related entities. As of December 31, 2025, ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and Michael Gelband together may be deemed to beneficially own 13,360 shares of Keros common stock, representing approximately 0.04% of the outstanding shares.
The shares are held directly by ExodusPoint Partners Master Fund, LP, while ExodusPoint Capital Management has investment and voting power under an investment management agreement. ExodusPoint Capital Partners is the general partner of ExodusPoint Capital Management, and Gelband controls both entities. The filers certify that the securities are not held to change or influence control of Keros.
Madison Avenue International LP and affiliated entities reported a passive ownership stake in Keros Therapeutics, Inc. common stock. As of February 17, 2026, they beneficially owned 823,707 shares of Common Stock, representing about 2.7% of the company, based on 30,466,069 shares outstanding as of October 31, 2025.
The filing lists Madison Avenue International LP, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha, who may each be deemed beneficial owners through their roles in the investment structure. They certify the shares are not held to change or influence control of Keros Therapeutics.
Keros Therapeutics, Inc. received an amended ownership report showing that Tang Capital and related entities no longer hold any of its common stock. The Schedule 13G/A (Amendment No. 1) reports that Tang Capital Management, Kevin Tang, and affiliated funds beneficially own 0 shares, representing 0% of the Keros common stock class as of the event date of 12/31/2025. The filing also confirms they have no sole or shared voting or dispositive power over any Keros shares and certifies the holdings are not intended to influence control of the company.
Keros Therapeutics, Inc. received an updated ownership filing from D. E. Shaw entities and David E. Shaw. As of December 31, 2025, they report beneficial ownership of 756,156 shares of common stock, representing 3.9% of the outstanding shares.
The filing shows no sole voting or dispositive power; all authority over these shares is shared through various D. E. Shaw investment vehicles. David E. Shaw may be deemed a beneficial owner through his control of related entities but expressly disclaims beneficial ownership. The reporting persons also certify the shares are not held to change or influence control of Keros.
The Vanguard Group reported beneficial ownership of 1,525,355 shares of Keros Therapeutics Inc common stock, representing 5% of the class as of 12/31/2025. Vanguard has shared voting power over 146,965 shares and shared dispositive power over all 1,525,355 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard states the holdings are in the ordinary course of business and not for changing or influencing control of Keros. An internal realignment effective 01/12/2026 shifted portfolio management and proxy voting to certain subsidiaries, which are expected to report ownership on a disaggregated basis.
Keros Therapeutics, Inc. furnished an updated corporate presentation for use in meetings with investors, analysts and others. The company made this updated presentation available on its website and also attached it as Exhibit 99.1 to this current report. The presentation is dated January 2026 and is meant to provide additional background on the business.
The company states that the information in this report, including Exhibit 99.1, is being furnished under Regulation FD and is not considered filed for purposes of certain liability provisions of the Securities Exchange Act. It will only be incorporated into other securities filings if specifically referenced there.
Keros Therapeutics CEO Jasbir Seehra reported a performance-based stock option update. On January 7, 2026, he was credited with 62,500 employee stock options with an exercise price of $63.61 per share, following certification of performance conditions by the board’s compensation committee.
The original grant, reported in February 2024, covered options for 125,000 shares subject to performance goals. The committee determined that targets tied to 62,500 shares were achieved, causing 31,250 shares to vest immediately and scheduling another 31,250 to vest on December 31, 2026, if he remains in continuous service through that date. Performance conditions tied to the remaining 62,500 shares were not met, and that portion of the option was forfeited for no consideration.